About Alpha Biopharma

Develops Zorifertinib, a next-generation EGFR tyrosine kinase inhibitor designed to treat advanced non-small cell lung cancer with central nervous system metastases, achieving 100% blood-brain barrier penetration. This first-in-class therapy addresses the unmet need for effective treatments in patients with brain metastases, supported by funding from national drug innovation programs.

```xml <problem> Advanced non-small cell lung cancer (NSCLC) often metastasizes to the central nervous system, and current treatments may not effectively penetrate the blood-brain barrier, leaving brain metastases inadequately addressed. This unmet need results in limited therapeutic options for patients with NSCLC and brain metastases. </problem> <solution> Alpha Biopharma is developing Zorifertinib, a next-generation EGFR tyrosine kinase inhibitor (TKI) specifically designed to treat advanced NSCLC with central nervous system metastases. Zorifertinib is engineered to achieve 100% blood-brain barrier penetration, ensuring effective drug concentrations in the brain. As a first-in-class therapy, Zorifertinib addresses the critical need for treatments that can effectively target and inhibit EGFR in brain metastases, potentially improving outcomes for patients with this challenging condition. The drug has received funding from national drug innovation programs, supporting its development and clinical evaluation. </solution> <features> - Next-generation EGFR tyrosine kinase inhibitor (TKI) - Designed specifically for advanced non-small cell lung cancer (NSCLC) with central nervous system metastases - Achieves 100% blood-brain barrier penetration - Unique design to avoid being a substrate for blood-brain barrier efflux transporters </features> <target_audience> The primary target audience includes patients with advanced non-small cell lung cancer who have developed brain metastases, as well as oncologists and medical professionals specializing in lung cancer treatment. </target_audience> ```

What does Alpha Biopharma do?

Where is Alpha Biopharma located?

Alpha Biopharma is based in Shanghai, China.

When was Alpha Biopharma founded?

Alpha Biopharma was founded in 2017.

How much funding has Alpha Biopharma raised?

Alpha Biopharma has raised 23900000.

Location

Shanghai, China

Founded

2017

Funding

23900000

Employees

6 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Alpha Biopharma

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

alphabiopharma.com 700+

Crunchbase

Founded 2017 – Shanghai, China

Funding

Estimated Funding

$20M+

Team (5+)

No team information available.

Company Description

Problem

Advanced non-small cell lung cancer (NSCLC) often metastasizes to the central nervous system, and current treatments may not effectively penetrate the blood-brain barrier, leaving brain metastases inadequately addressed. This unmet need results in limited therapeutic options for patients with NSCLC and brain metastases.

Solution

Alpha Biopharma is developing Zorifertinib, a next-generation EGFR tyrosine kinase inhibitor (TKI) specifically designed to treat advanced NSCLC with central nervous system metastases. Zorifertinib is engineered to achieve 100% blood-brain barrier penetration, ensuring effective drug concentrations in the brain. As a first-in-class therapy, Zorifertinib addresses the critical need for treatments that can effectively target and inhibit EGFR in brain metastases, potentially improving outcomes for patients with this challenging condition. The drug has received funding from national drug innovation programs, supporting its development and clinical evaluation.

Features

Next-generation EGFR tyrosine kinase inhibitor (TKI)

Designed specifically for advanced non-small cell lung cancer (NSCLC) with central nervous system metastases

Achieves 100% blood-brain barrier penetration

Unique design to avoid being a substrate for blood-brain barrier efflux transporters

Target Audience

The primary target audience includes patients with advanced non-small cell lung cancer who have developed brain metastases, as well as oncologists and medical professionals specializing in lung cancer treatment.